Pfizer Advances Lyme Vaccine Regulatory Filings
Pfizer discussed regulatory plans for its Valneva-partnered Lyme disease vaccine on its third-quarter earnings call.
Updated on Nov. 4, 2026 in COVID-19
Live Poll
Would you get a Lyme disease vaccine if one became available in your area?
Pfizer discussed regulatory plans for its Lyme disease vaccine, developed with Valneva, on its third-quarter earnings call. The European Medicines Agency confirmed receipt of the application in August, and the vaccine has also been filed in Canada.
Why it matters
Rising severity and incidence of Lyme disease in the United States is raising awareness of the illness, and an approved vaccine would add a preventive option. Regulatory progress in Europe and Canada sets the timeline for availability beyond the United States.
The only dated regulatory milestone is the European Medicines Agency's confirmation of receipt in August, with no day specified. Pfizer has not disclosed a timeline for the European launch, and the outcome of U.S. regulatory discussions remains unknown.
The players
Pfizer
Pfizer is a major American pharmaceutical company that markets vaccines and medicines globally.
Valneva
Valneva is a French vaccine company that partners with Pfizer on the Lyme disease vaccine.
European Medicines Agency
The European Medicines Agency is the European Union body responsible for scientific evaluation of medicines, which confirmed receipt of Pfizer's application.
The details
Pfizer confirmed on its call that it is in ongoing discussions with the FDA about a regulatory submission for the vaccine, designated PF-07307405. Pfizer plans to sell the vaccine in Europe through its existing sales force and pharmacy relationships in tick-borne endemic areas, and it owns a tick-borne encephalitis vaccine portfolio marketed in Europe.
Timeline
August: The European Medicines Agency confirmed receipt of Pfizer's Lyme vaccine application.
Q4 2026: An update on U.S. regulatory discussions is expected this quarter.
End of 2026: Analysts have suggested the FDA filing could be completed.
2027: The CHMP is set to deliver its verdict on European approval.
Regulatory Pathway
The filing follows the European Medicines Agency's centralized review pathway, which culminates in a Committee for Medicinal Products for Human Use verdict expected in 2027. Canada's parallel filing places the vaccine on a separate national review track.
If approved, the vaccine would give people in tick-endemic areas a preventive option against Lyme disease, which is increasingly severe and common in the United States. Availability will depend on regulatory timelines in each country, and no launch date has been given for Europe.
The takeaway
Regulatory timelines for new vaccines unfold across several agencies and years, so approval in one region does not guarantee availability elsewhere. Readers in tick-endemic areas should track national regulatory announcements for updates on when a Lyme vaccine could become available.
What happens next
An update on U.S. regulatory discussions is expected this quarter, and the CHMP is set to deliver its European verdict in 2027.
Further reading
For more on vaccine development and public health, explore the COVID-19 section.
Source note: This article includes information reported by Pharma.
Live Poll
Would you get a Lyme disease vaccine if one became available in your area?
